In CDR-Life we make transformative cancer immunotherapies
CDR-Life AG
Incorporated
01.02.2017Headquarters
SchlierenSupport
CDR-Life is a privately held, biotherapeutics company leveraging its unique antibody technology, M-gager®, to target highly cancer-specific intracellular proteins presented on the major histocompatibility complex (MHC). CDR-Life is advancing a robust pipeline of novel fully cancer-directed T cell engagers in various solid tumors. The team behind CDR-Life has extensive experience in all key areas of biologics development, hold numerous patents, and has previously invented new marketed medicines. CDR-Life has a strategic partnership with Boehringer Ingelheim to develop an antibody fragment-based therapeutic for geographic atrophy, a leading cause of blindness worldwide. For more information, please visit cdr-life.com and follow the Company on Twitter and LinkedIn.
News
New leaders with a fresh perspective for several startups (startupticker.ch)
Positive clinical progress in the biotech scene (startupticker.ch)
Triumphs and a setback in the biotech sector (startupticker.ch)
New milestones for life sciences startups (startupticker.ch)
CDR-Life advances into the clinical phase (startupticker.ch)
CDR Life obtains milestone payment (startupticker.ch)
The 18 most promising biotech startups, according to investors (TOP 100)
Change of management in pursuit of growth (startupticker.ch)
CDR-Life Closes $76 million Series A Funding (startupticker.ch)
CDR-Life raises USD 76 million in Series A funding to support advancement of its transformative cancer immunotherapies (venturelab.swiss)
CDR-Life moves towards clinical trials (startupticker.ch)
Techshare reveals its 2021 cohort with 13 Swiss startups (startupticker.ch)
Strong Swiss delegation at Bio Europe (startupticker.ch)
Eleven Swiss start-ups on the virtual BIO Digital stage (startupticker.ch)
CDR-Life inks lucrative collaboration agreement with Boehringer Ingelheim (startupticker.ch)